Read More

The business of ‘female tech’ is growing

(NYTIMES) - Women represent half of the planet's population. Yet tech companies catering to their specific health needs represent a minute share of the global tech market. Tapping that spending power, a multitude of apps and tech companies have sprung up in the last decade to address women's needs, including tracking menstruation and fertility, and offering solutions for pregnancy, breastfeeding and menopause. Medical start-ups also have stepped in to prevent or manage serious conditions such as cancer. "The market potential is huge," said psychiatrist Michelle Tempest, a partner at the London-based healthcare consultancy Candesic. "There's definitely an increasing appetite for anything in the world which is technology, and a realisation that female consumer power has arrived - and that it's arrived in healthcare." She said one reason women-related needs had not been focused on in the field of technology was that life sciences research was overwhelmingly "tailored to the male body". In 1977, the US Food and Drug Administration excluded women of child-bearing age from taking part in drug trials. Since then, women have been underrepresented in drug trials, because of a belief that fl...

Read More

Scivita Medical Raises Nearly RMB0.4 Billion in Series A Funding Round and Strives to Build A World-leading Platform for Innovative Products in Endoscope and Related Fields

HONG KONG, Apr 26, 2021 - (ACN Newswire via SEAPRWire.com) - Scivita Medical Technology Co., Ltd. ("Scivita Medical") today announced that it has raised nearly RMB0.4 Billion in Series A funding round, which has become one of the highest financing projects in the field of endoscope in China in recent years. The investment was jointly led by GL Ventures and Lilly Asia Ventures, with contribution from Matrix Partners China, Medtronic, Chengwei Capital and Shanghai Innochip Investment. The successful completion of the Series A funding round reflects the recognition of Scivita Medical in the field of endoscope and the expectation of its future development from the capital market and industrial strategic partners. Scivita Medical will strive to build the world's leading platform for innovative products in endoscope and related fields.Founded by Dr. ZHANG Yi and Dr. CHEN Dong, Scivita Medical is headquartered in Suzhou Industrial Park with R&D centers in Suzhou, China, and Tokyo, Japan, focusing on the image processing R&D and technology innovation of endoscope. Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional ima...

Read More

Olympus Opens New Global HQ for Therapeutic Solutions Division and U.S. Medical Business

TOKYO, Apr 8, 2021 - (ACN Newswire via SEAPRWire.com) - Olympus Corporation ("Olympus" - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today the opening of a new facility in Westborough, MA, to serve as the global headquarters for its Therapeutic Solutions Division (TSD) and its medical business in the United States. Olympus opens global headquarters for Therapeutic Solutions and Medical Business in Westborough, MA, U.S.New facility features Olympus Continuum Training and Education Center and Olympus OR Innovation Center ShowroomGlobal Therapeutic Solutions headquarters opening in the U.S. is part of Transform Olympus initiativeOlympus has identified TSD as a strategic focus for growth and shifted its global head of TSD from Tokyo to the U.S. to have better access to a key medical industry cluster and generate growth through stronger business opportunities. Since the Transform Olympus initiatives were unveiled in 2019, many U.S.-based executives have been leading TSD growth; Olympus has dramatically expanded the business with acquisitions, as well as through organic growth.The new 150,000-square-foot facility in Westborough will accommodat...

Read More

Universal Medical Announced its 2020 Annual Results

HONG KONG, Mar 31, 2021 - (ACN Newswire via SEAPRWire.com) - The board (the "Board") of directors (the "Directors") of Genertec Universal Medical Group Company Limited (the "Company" or "Universal Medical") is pleased to announce the annual results of the Company and its subsidiaries (together, the "Group") for the year ended 31 December 2020.2020 ANNUAL RESULTS HIGHLIGHTS-- The revenue amounted to approximately RMB8,521.2 million, representing an increase of 25.0% as compared with that of approximately RMB6,815.6 million for 2019.-- The profit before tax amounted to approximately RMB2,365.0 million, representing an increase of 6.9% as compared with that of approximately RMB2,211.9 million for 2019. -- The profit for the year attributable to owners shareholders of the parent amounted to approximately RMB1,647.5 million, representing an increase of 10.7% as compared with that of approximately RMB1,488.7 million for 2019. -- The total assets amounted to approximately RMB61,511.0 million, representing an increase of 6.3% as compared with that of approximately RMB57,852.5 million as at 31 December 2019.-- The equity attributable to owners of the parent amounted to approximately RMB10,7...

Read More

Zhong Ji Longevity Science Announces 2020 Annual Results

HONG KONG, Mar 30, 2021 - (ACN Newswire via SEAPRWire.com) - Zhong Ji Longevity Science Group Limited ("Zhong Ji Longevity Science", together with its subsidiaries, the "Group"; stock code: 0767.HK) is pleased to announce its audited consolidated annual results for the year ended 31 December 2020 ("reporting year"). The Group was principally engaged in the business of money lending, securities and other investments, financial and investment advisory, as well as property investment before. The aging population across the globe has fuelled growing demand for health supplements and longevity products. The Group has discovered the huge potential and invested substantial resources in mapping out its blueprint in the longevity science sector, and subsequently realised the transformation of its business during the reporting year by extending its business to the development and sales of Nicotinamide Mononucleotide (NMN) longevity biological products with great breakthroughs. Meanwhile, the Group is committed to establishing a leading ecosystem platform in longevity science, tapping into the development of cell and gene therapy, as well as advanced medical technology.During the reporting ye...

Read More

China Medical System (00867) Ushers in a Revaluation with its Continuous Growth and Synergy between Innovative Business and New Businesses

HONG KONG, Mar 30, 2021 - (ACN Newswire via SEAPRWire.com) - Turnover and net profit increased at the same time, innovative pipeline continued to expand, and the synergy between its businesses became increasingly obvious .....China Medical System Limited (the "Company" or "CMS"), who has just released its annual results, has brought too many surprises to the market.In recent years, CMS has successfully completed its transformation from an "old CMS" driven by sales and promotion to a "new CMS" driven by innovative R&D by deepening its innovative pipeline and promoting the synergistic development of multiple business lines. Now, with its strength in business development and sales promotion, the innovative pipeline and new businesses continued to expand, which has become a powerful driving force to lift the Company's valuation ceiling.According to zhitongcaijing.com app, on March 16, CMS released its 2020 annual results. The financial report shows that the Company's overall performance achieved solid growth in 2020, with annual turnover up 14.4% y-o-y to RMB6.946 billion, net profit up 30.7% y-o-y to RMB2.556 billion.In fact, the Company's ability to grow against the odds in an en...

Read More

Black Spade Capital Announces Acquisition of iRad Medical Holding

HONG KONG, Mar 22, 2021 - (ACN Newswire via SEAPRWire.com) - Black Spade Capital Limited ("Black Spade Capital"), the family office of the casino magnate Lawrence Ho, has announced the acquisition of iRad Medical Holding Limited ("iRad"), a Hong Kong-based diagnostic imaging practice. Following the acquisition, Black Spade Capital will be the majority shareholder of iRad. (From left to right)Dr. Matthew Ngan, Chairman of iRad; Ms. Crystal Yeung, Marketing Manager of iRad; Mr. Kin Wong, CEO of iRadiRad currently operates four radiology clinics in prime locations across Hong Kong, including in Central, Jordan and Mongkok. Moreover, the practice has a workforce of close to 100 radiologists, radiographers, nurses and supporting staff members, who provide a wide spectrum of modalities including magnetic resonance imaging (MRI), computed tomography (CT), mammography, ultrasound and X-ray. iRad will continue to be led and managed by the founding team of the medical group, while Black Spade Capital will be working closely with the iRad management on strategies for its development and market expansion.Mr. Dennis Tam, President and CEO of Black Spade Capital, said, "We are very pleased with ...

Read More

Fujitsu Embarks on Joint Research with National Cancer Center Japan to Create New Services for Drug Development and Clinical Trials

TOKYO, Mar 18, 2021 - (JCN Newswire via SEAPRWire.com) - Fujitsu today announced it has concluded a comprehensive collaborative research agreement with National Cancer Center Japan. The joint research will center on exploring ways that real-world data(1), including medical information from electronic records, can be leveraged to contribute to the development of new drugs, clinical trials, and preventive medicine in pharmaceutical companies.Through its joint research with the National Cancer Center, Fujitsu aims to create new value through a wide range of information and analysis services by creating an anonymized personal health record scheme(2) (PHR), which includes case study information and health information on patients visiting the National Cancer Center Hospital East. Fujitsu additionally seeks to create a platform for providing pharmaceutical companies with data that can be used for drug development and preventive medicine. Fujitsu will establish a new model to process medical information from electronic medical records into highly secure statistical data to improve the efficiency of clinical trials and supports active participation in international joint clinical trials by ...

Read More

Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer

Foster City, CA, and Hangzhou, China, Mar 9, 2021 - (ACN Newswire via SEAPRWire.com) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of K. Peony Yu, M.D. as Chief Medical Officer. Dr. Yu will assume the role on March 16, 2021. Apollomics also announced that Sophie (Zhengjie) Sun has been named as Senior Vice President, Corporate Development and will be based in the Company's China office. Both executives report to Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of the Company."Dr. Yu joins us with an incredible leadership and global drug development background that is a perfect fit for Apollomics, and we are thrilled to welcome her to our team," said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "Peony's extensive cross border experience includes managing teams in both the U.S. and China and overseeing multiple functions including clinical development, regulatory strategy and medical affairs. Peony will be instrumental in our efforts to advance our current assets and expand our development pipeline." "Apollom...

Read More

Doctor jailed and caned for assaulting girlfriend no longer allowed to practise

SINGAPORE - The doctor who was convicted last year of physically assaulting his then girlfriend, leaving her with a brain haemorrhage and fractures, has been struck off the Register of Medical Practitioners. Clarence Teo Shun Jie was referred to the Singapore Medical Council's disciplinary tribunal last year, soon after his sentencing in June which saw him receive three years, six months and two weeks' jail, with four strokes of the cane and a fine of $4,000. Under the Medical Registration Act, a medical practitioner convicted of a crime that implies "a defect in character which makes him unfit to practise medicine" may be referred to the disciplinary tribunal. Punishment can include fines, suspensions and removal from the register of medical practitioners. Teo, who was a locum, physically assaulted his then girlfriend on several occasions in 2017. He had met the victim in February that year on a dating app. About a month later, during an argument, Teo assaulted her for the first time. He did it again later that month and a third time in August 2017, assaulting her in his flat. He locked her in a room and repeatedly assaulted her when she refused to have sexual intercourse with him...

Read More

Covid-19 pandemic a shot in the arm for digital health service Speedoc

SINGAPORE - Seeing a doctor has taken on a whole new meaning amid the pandemic with plenty of patients keen to keep a distance, which is where digital health app Speedoc comes in. The app has experienced a spike in demand over the past year, whether from people wanting to book urgent face-to-face treatment or those preferring consultations without leaving home. Chief executive Shravan Verma notes that many people think twice about visiting clinics and hospitals as they want to limit potential exposure to the coronavirus and more are turning to alternative ways of getting medical care. Speedoc's revenue surged nearly 400 per cent last year over 2019's level while app downloads rose by more than 200 per cent from a year ago. "We already had a network of healthcare professionals in various parts of Singapore, so when the pandemic occurred, it was very easy to deploy them to provide medical care in their vicinity," said Dr Verma. The app allows users to book a doctor or nurse for home visits 24/7 or have a tele-consultation. They can also book an ambulance for non-emergency situations. The surging demand prompted Speedoc to hire more than 70 full and part-time staff - mainly doctors an...

Read More

China Medical System (0867.HK) Acquires a Dermatology Specialty Company: A Tough Player the Race

HONG KONG, Feb 5, 2021 - (ACN Newswire) - On February 1, China Medical System (0867.HK) announced that its subsidiary had acquired Luqa Ventures Co., Limited ("Luqa"), a dermatology specialty company. This acquisition expanded its product portfolio to include Luqa's dermatology products and marked the first foray into the medical aesthetic industry for China Medical System.Why medical aesthetics? What is the significance of this acquisition?1. Consolidating the Skin Management Business and Entering the Medical Aesthetic Market: Acquiring Luqa to Explore a New Growth EngineAccording to its official website, established in 2010, Luqa is an innovative enterprise with skin treatment and medical aesthetic solutions as its core business.Its founder, Mr. Luo Benwei, is experienced in medicine and was involved in Asia's skin management and medical aesthetic industry before establishing Luqa. In 2005, as Almirall's youngest international business development manager, Mr. Luo successfully drove the company's products into markets in Africa, the Middle East, West Asia and East Asia.China Medical System recognized Luqa's many advantages, including: its abundant overseas resources of medical ae...

Read More

Olympus Supports Dissemination of Endoscopic Procedures for Colorectal Cancer in Russia

TOKYO, Feb 4, 2021 - (ACN Newswire) - Olympus Corporation (Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has been selected(1) by Japan's Ministry of Health, Labour and Welfare (MHLW) to implement the Japan-Russia Medical Cooperation Promotion Project in the field of endoscopy for the fiscal year ending March, 2021. Under the project, Olympus will promulgate gastrointestinal endoscopic/laparoscopic techniques in support of a five-year oncology plan launched by the Russian government in 2019.(2)As part of the project, Olympus will facilitate online training programs for gastrointestinal endoscopic/laparoscopic techniques taught by Japanese oncology specialists for Russian endoscopists and oncologists. The bilateral project is being carried out in cooperation with Russia's two premier cancer centers, the N. N. Blokhin Cancer Research Center and the P. Hertsen Moscow Oncology Research Institute branch of the Russian National Medical Research Radiological Centre (NMRRC) as well as Asian Medical Education and Training Support (AMETS).(3) As part of the project's initiatives, Olympus commits to disseminate Japan's world-leading tech...

Read More

Olympus to Acquire Quest Photonic Devices B.V. to Bolster Surgical Endoscopy Capabilities

Tokyo / Hamburg, Jan 28, 2021 - (ACN Newswire) - Olympus Corporation (Olympus - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced that it has entered into an agreement to acquire Quest Photonic Devices B.V. (Quest - CEO: Richard Meester) for up to EUR50 million including milestone payments to strengthen its surgical endoscopy capabilities.Headquartered in the Netherlands, Quest offers advanced fluorescence imaging systems (FIS) for the medical field, enabling more surgical endoscopy capabilities, compared to conventional imaging technologies.Fluorescence imaging refers to special light imaging technologies that utilize the properties of fluorescent dyes directed to specific anatomical structures. By using targeted dyes, in combination with specific light wavelengths, tissues or lesions that are nearly invisible under normal white light become visible. Olympus' existing laparoscopic imaging system, VISERA ELITE II, is already equipped with fluorescence imaging technology. VISERA ELITE II uses near-infrared light to identify blood vessels or lymph nodes under the surface tissues, aiming to assist surgeons in performing safer procedures wit...

Read More

Health Check Podcast: Get healthy living tips for 2021

Fortnightly on Wednesdays, get healthier living tips as The Straits Times' senior health correspondent Joyce Teo chats with expert guests. These are the best episodes of our Health Check Podcast series so far. Health Check Ep 6: Can soursop or ketogenic diets be used to treat and control cancer? (featuring Dr Wong Seng Weng, medical director and consultant medical oncologist at The Cancer Centre) Health Check Ep 45: How to age well and achieve a lower biological age (featuring anti-ageing expert, Prof Brian Kennedy, the director of the NUHS Centre for Healthy Longevity) Health Check Ep 46: Is there such a concept as an anti-ageing diet? (featuring anti-ageing expert, Prof Brian Kennedy, the director of the NUHS Centre for Healthy Longevity) Health Check Ep 15: Forget about raising your good cholesterol? (featuring Dr Michael Lim, the medical director of MWH Heart, Stroke & Cancer Centre) Health Check Ep 39: Smokers at higher risk during Covid-19 times (featuring Dr Lambert Low, a consultant at the National Addictions Management Service at the Institute of Mental Health) Health Check Ep 16: How to get your hawker food fix without risking a heart attack (featuring Dr Michael Lim, the...

Read More

Olympus and Hitachi Announce Long-Term Business Alliance regarding Endoscopic Ultrasound Systems

TOKYO, Jan 6, 2021 - (JCN Newswire) - Olympus Corporation (TSE:7733) and Hitachi, Ltd. (TSE:6501) have signed a five-year contract to jointly develop Endoscopic Ultrasound Systems (EUS). Hitachi will also continue to supply diagnostic ultrasound systems and related parts used in EUS to Olympus under this contract.EUS consist of a diagnostic ultrasound system and ultrasound flexible endoscopes. They are used in examinations to evaluate the stage of cancer in the liver, pancreas, and bronchus, as well as in minimally-invasive care, contributing to the medical treatment.Hitachi's diagnostic imaging-related business is expected to be transferred to FUJIFILM Corporation, subject to customary closing conditions and regulatory approvals. The agreement between Hitachi and Olympus will be valid after such transfer.Hironobu Kawano, Division Head of the Endoscopic Solutions Division, Olympus Corporation, said, "Olympus aims to improve patients' quality of life through early diagnosis made available with Endoscopic Ultrasound Systems. Our long-standing partnership with Hitachi has built a strong foundation of products and technology development for endoscopic ultrasound diagnosis, and we are v...

Read More

Mediwelcome: Key Player in the Gold Track, is Forming a Head Leading Advantage

HONG KONG, Jan 6, 2021 - (ACN Newswire) - In recent years, with the improvement of the economic level and the development of the aging population, as well as the unhealthy living habits of adolescents and other factors, the incidence of cardiovascular and cerebrovascular diseases has shown an obvious trend of increase. According to the report, there are about 391 million patients with cardiovascular and cerebrovascular diseases in China in 2019, accounting for about 26.8 percent of the national total population. The number of patients with cardiovascular and cerebrovascular diseases in China is expected to further increase to about 429 million in 2024.In this huge market space, Mediwelcome, a Beijing-based provider of comprehensive medical marketing solutions for cardiovascular and cerebrovascular diseases, faces excellent development opportunities. Its Hong Kong shares (02159.HK) will list on January 19, so further exploration of the company's quality and reputation follows.1. Business support from three segments, leading the industry in medical track segmentationFounded in 2000, Mediwelcome is China's largest provider with comprehensive medical marketing solutions for cardiovascu...

Read More

Mediwelcome: Reasonable valuation with HK listing on track for January 19

HONG KONG, Jan 6, 2021 - (ACN Newswire) - With the improvement in China's economic level, the ageing population and the unhealthy living habits of adolescents, the incidence of cardiovascular and cerebrovascular disease is increasing. There were 391 million patients with cardiovascular and cerebrovascular diseases in China in 2019, or 26.8% of the population. The incidence of cardiovascular and cerebrovascular disease in China will increase to about 429 million in 2024.In this huge market space, Mediwelcome, a Beijing-based provider of comprehensive medical marketing solutions for cardiovascular and cerebrovascular diseases, faces excellent development opportunities. Its Hong Kong shares (02159.HK) will list on January 19, so further exploration of the company's quality and reputation follows.1. Business support from three segments, leading the industry in medical track segmentationFounded in 2000, Mediwelcome is China's largest provider with comprehensive medical marketing solutions for cardiovascular and cerebrovascular diseases. At present, its business layout mainly involves three areas: comprehensive medical marketing solutions, Internet hospitals and CRO services. The new bus...

China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level

HONG KONG, Dec 22, 2020 - (ACN Newswire) - On December 17, the largest index provider, Morgan Stanley Capital International (MSCI) updated a report on the ESG (Environmental, Social and Governance) rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. According to the report, China Medical System's ESG rating has been upgraded from "BBB" to "AA", surpassing 88% of companies in the global pharmaceutical industry, and symbolizing that the Company has reached a leading level among its global peers in ESG management.In the report, MSCI recognized China Medical System's outstanding performance in Corporate Governance, Corporate Behavior, Product Safety and Quality, Human Capital Development and Access to Health Care, and commented: "Leads peers in business ethics and talent management practices". MSCI also gave a positive assessment of the Company's Corporate Behavior, "China Medical System has evidence of detailed policies on business ethics and corruption".There are seven levels of the MSCI-ESG rating, from the highest to the lowest are: AAA, AA, A, BBB, BB, B an...

China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level

HONG KONG, Dec 21, 2020 - (ACN Newswire) - Morgan Stanley Capital International (MSCI) issued a report on December 17 upgrading the ESG (Environmental, Social and Governance) Rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. China Medical System's ESG Rating has been upgraded from "BBB" to "AA", surpassing 88% of companies in the global pharmaceutical industry, symbolizing that the Company has attained a level among its global peers in ESG management.MSCI recognized China Medical System's outstanding performance in Corporate Governance, Corporate Behavior, Product Safety and Quality, Human Capital Development, and Access to Health Care, noting that the Company "Leads peers in business ethics and talent management practices". MSCI also gave a positive assessment of the Company's Corporate Behavior, "China Medical System has evidence of detailed policies on business ethics and corruption".There are seven levels of the MSCI-ESG Rating, from the highest to the lowest are AAA, AA, A, BBB, BB, B, and CCC. Among them, companies with AA or AAA ratings are consider...